A Multiple-center Study on the Effect of Different Ways of Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With More Than 50% Solid Components

Launched by SHANGHAI ZHONGSHAN HOSPITAL · Oct 8, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at how different methods of removing lymph nodes affect the outcomes for patients with small lung nodules, specifically those that are less than 3 centimeters in size and have more than half of their area made up of solid components. The study aims to gather information that could help improve treatment options for these patients.

To be eligible for this trial, participants need to be between 18 and 75 years old and have been diagnosed with a specific type of lung nodule called a ground-glass nodule (GGO) that hasn’t changed after three months of monitoring. The nodules must meet certain size requirements, and patients should be able to undergo a surgical procedure called lobectomy to remove part of the lung. Those who have received certain treatments like chemotherapy or radiation, or who have used specific medications, won’t be able to take part in the study. Participants can expect to be closely monitored throughout the trial, and they will need to give their written permission to join. This study is currently recruiting participants and aims to help researchers better understand how to manage these types of lung nodules effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged between 18 and 75 years;
• • 2. GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having been re-examined by thin-section CT);
• • 3. The maximum diameter of the GGO is smaller than 3cm;
• • 4. The maximum diameter of the solid component in the GGO is more than 50%;
• • 5. The patient is able to undergo the lobectomy
• • 6. The patient is able to understand and comply with the study and has provided written informed consent.
• Exclusion Criteria:
• • -
• Patients meeting any of the following criteria are not eligible for this trial:
• • 1. Patients with a history of using immunosuppressive or hormonal drugs;
• • 2. Patients receiving radiotherapy or chemotherapy;
• • 3. Patients who fail to comply with our follow-up strategy;
• • 4. Other situations that are not in conformity with the standards and requirements of this trial.